Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 513 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infection, Human Immunodeficiency Virus I Clear all
Terminated Phase 2 Interventional

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW873140, Kaletra (lopinavir/ritonavir)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

NCT00001090
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

NCT00001118
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
24
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

NCT00000847
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

NCT00001026
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, HIVAC-1e
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
2
States / cities
Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

NCT00000792
View directory record Official record
Conditions
HIV Infections
Interventions
Hypericin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002299
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Interferon beta-1b, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 7:44 PM EDT
Active, not recruiting Not applicable Interventional

Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments

NCT05110963
View directory record Official record
Conditions
HIV I Infection
Interventions
Uniform Standard of Care Counseling, Behavioral Self-Regulation Skills Counseling, Behavioral Self-Regulation Skills Counseling + Stigma Management
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
3,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Storrs, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

NCT00002136
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tecogalan sodium
Drug
Lead sponsor
Daiichi Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

Telephone-delivered Behavioral Interventions to Reduce Risky Sexual Behavior in HIV-positive Late Middle-age and Older Adults

NCT01499706
View directory record Official record
Conditions
Unsafe Sex
Interventions
1-session of telephone-administered motivational interviewing, 4-session telephone-administered motivational interviewing
Behavioral
Lead sponsor
Ohio University College of Osteopathic Medicine
Other
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2011 · Synced Oct 13, 2026, 7:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

NCT04303117
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
PDS01ADC, M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

NCT00000749
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).

NCT00000393
View directory record Official record
Conditions
HIV Infections, Cognition Disorders
Interventions
Peptide T
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1988
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 13, 2026, 7:44 PM EDT
Not yet recruiting Phase 1 Interventional

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

NCT06233331
View directory record Official record
Conditions
Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions
Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

NCT00000742
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of SAR441236

NCT03705169
View directory record Official record
Conditions
HIV-1-infection
Interventions
SAR441236, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tenofovir Rectal Douche to Prevent HIV Transmission

NCT04016233
View directory record Official record
Conditions
HIV/AIDS, HIV Prevention
Interventions
Tenofovir douche
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

NCT00441909
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781, UC-781 placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of 935U83 in HIV-Infected Patients

NCT00002338
View directory record Official record
Conditions
HIV Infections
Interventions
Raluridine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

NCT01057121
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 13, 2026, 7:44 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

NCT00189904
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lexington, Kentucky • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 13, 2026, 7:44 PM EDT